Here are three psychedelics stocks you should watch
Besides Mindcure investors should put these three companies on their radar.
ATAI Life Sciences N.V. (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are three stocks engaged in the commercialization of psychedelics for medical use. Investors should keep them on their radar as they have massive long-term potential. Norms and regulations in society can change over the span of a few generations. We saw that with the rise of the cannabis industry. A few decades ago, most people opposed the recreational and medicinal use of marijuana. Today, medical marijuana has almost unanimous approval, while a majority is in favor of legalization for recreational use. We may now be going through the same process with psychedelic drugs like LSD, psilocybin, and MDMA. There is promising research and evidence that these substances can help with mental illness and anxiety much more effectively than traditional treatments with fewer side effects. Additionally, psychedelics have the power to help on a much more fundamental level than just treating symptoms. Research and clinical trials are being conducted on these substances, while state lawmakers in more liberal enclaves are considering legalizing them for medical purposes. Last year Oregon became the first state to legalize its use for medical purposes. Investors are also starting to take notice as there is significant commercial potential. 3 stocks working on developing treatments out of psychedelics are ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD).